Cooking Education and Adapted Physical Activity in Allografted Patients (NUTRITION)

February 23, 2024 updated by: Centre Hospitalier Universitaire de Nice

Impact of Cooking Education and Adapted Physical Activity on Nutritional Status and Quality of Life of Patients Treated by Allo Stem Cell Transplantation

Majority of patients after allo stem cell transplantation have malnutrition and decrease of physical activities. This state impacts on quality of life and on outcome of some complications like infections, graft versus host disease and could decrease the overall survival. In this study, the investigators propose cooking education and adapted physical activity to improve that. Cooking education and adapted physical activity at home will be performed by two famous chefs for the first one and by a sportive coach for the second every twice week.

Study Overview

Status

Completed

Conditions

Detailed Description

Bone marrow transplantation is the main strategy to cure leukemia and others hematopoietic malignancies. It includes a first step of chemotherapy during several days (combined sometimes to radiotherapy), a second step of stem cells infusion and a third step of management of complications during several months: side effects, infections or graft versus host disease (GvHD). Symptoms are cutaneous, hepatic and digestive (nausea, diarrhea, vomiting) and could be unfortunately followed by the death of the patients.

Nutritional status is known to be important during the treatment of all cancers. After bone marrow transplantation, patients could have some digestive disorders that could induce malnutrition that could have an impact of time of hospitalization, intensity of complications and outcome of these ones.

When patients go back home after allo stem cell transplantation, they take several medicines, they have digestive side effects of past treatments could alter mucous, taste and all digestive tracts. During at least 100 days, patients take immunosuppressive therapies and they are going to develop new immune system. Therefore, they must follow some food rules to avoid infectious diseases. Patients feel some difficulties to eat good food and refuse often social activities. All of these have an impact on quality of life and induce an increase of malnutrition observed already directly after allo stem cell transplantation. Some complications could also increase malnutrition like digestive GvHD or digestive infections. Malnutrition could also induce physical troubles. Patients need until one year to recover physical conditions before the disease.

The aims of the study are to improve nutritional status and physical activity of patients after allo stem cell transplantation.

The investigators propose at all patients included in the study cooking education and adapted physical activity every twice week in alternance. Cooking education will be performed by two famous chefs in their kitchens. Patients (until 3 months after bone marrow transplantation) and one member of their family are invited to cook and taste. They will receive lot of advice to make several recipes at home and will adapt their cooking methods to respect food rules. Adapted physical activity will be performed by a sportive coach at home. The coach will give them some physical exercises to do between two sessions.

Patients, aged more than 18 years old and signing the consent form, are included in the study before allo stem cell transplantation. Nutritional status evaluation will be performed by a nutritionist using some tests: sit up test, hand grip, bioelectrical impedance analysis, mid upper arm circumference, analogic evaluation of appetite, blood tests: C reactive protein, transthyretin, albumin. The nutritionist will analyze also body mass index, the weight loss percent, the subjective global assessment, the health quality of life assessment.

Evaluation will be performed before allo stem cell transplantation, at day 0, 30, 100 and 300.

The aims of the study are to observe an improvement of nutritional status, quality of life, a decrease of the number of infections and GvHD and at the end an increase of overall survival.

Study Type

Interventional

Enrollment (Actual)

25

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Nice, France, 06200
        • CHU de Nice - Hôpital de l'Archet

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patient at least 18 years old
  • Having been an allograft of CSH
  • Patient having read and understood the information note related to the study, and signed the informed consent form.

Exclusion Criteria:

  • Patient requiring nutritional support by enteral or parenteral route at J30
  • Follow-up of the patient considered difficult by the investigator.
  • Patient with a linguistic or psychic disability to understand the information.
  • Vulnerable patient under legal protection

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: cooking Education and adapted physical activity
cooking Education and adapted physical activity on patients after allo stem cell transplantation
cooking Education and adapted physical activity on patients after allo stem cell transplantation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Body mass index
Time Frame: at pre transplant
Body mass index
at pre transplant
Body mass index
Time Frame: at Day 0
Body mass index
at Day 0
Body mass index
Time Frame: at Day 30
Body mass index
at Day 30
Body mass index
Time Frame: at Day 100
Body mass index
at Day 100
Body mass index
Time Frame: at Day 300
Body mass index
at Day 300
visual analogic scale of appetite
Time Frame: at pre transplant
It allows a visual assessment, by the patient himself, of his food intake, using an analog scale, or a choice of portions consumed.Visual analog scales (VAS) are reliable tools to evaluate hunger and satiety at point of food consumption. Score from 1 to 10. There are not better or worse values.
at pre transplant
visual analogic scale of appetite
Time Frame: at Day 0
It allows a visual assessment, by the patient himself, of his food intake, using an analog scale, or a choice of portions consumed.Visual analog scales (VAS) are reliable tools to evaluate hunger and satiety at point of food consumption. Score from 1 to 10. There are not better or worse values
at Day 0
visual analogic scale of appetite
Time Frame: at Day 30
It allows a visual assessment, by the patient himself, of his food intake, using an analog scale, or a choice of portions consumed.Visual analog scales (VAS) are reliable tools to evaluate hunger and satiety at point of food consumption. Score from 1 to 10. There are not better or worse values
at Day 30
visual analogic scale of appetite
Time Frame: at Day 100
It allows a visual assessment, by the patient himself, of his food intake, using an analog scale, or a choice of portions consumed.Visual analog scales (VAS) are reliable tools to evaluate hunger and satiety at point of food consumption. Score from 1 to 10. There are not better or worse values
at Day 100
visual analogic scale of appetite
Time Frame: at Day 300
It allows a visual assessment, by the patient himself, of his food intake, using an analog scale, or a choice of portions consumed.Visual analog scales (VAS) are reliable tools to evaluate hunger and satiety at point of food consumption. Score from 1 to 10. There are not better or worse values
at Day 300
sit up test
Time Frame: at pre transplant
sit up test
at pre transplant
sit up test
Time Frame: at Day 0
sit up test
at Day 0
sit up test
Time Frame: at Day 30
sit up test
at Day 30
sit up test
Time Frame: at Day 100
sit up test
at Day 100
sit up test
Time Frame: at Day 300
sit up test
at Day 300
bio electrical impedance analysis,
Time Frame: at pre transplant
it's measuring the resistance of biological tissues
at pre transplant
bio electrical impedance analysis,
Time Frame: at Day 0
it's measuring the resistance of biological tissues
at Day 0
bio electrical impedance analysis,
Time Frame: at Day 30
it's measuring the resistance of biological tissues
at Day 30
bio electrical impedance analysis,
Time Frame: at Day 100
it's measuring the resistance of biological tissues
at Day 100
bio electrical impedance analysis,
Time Frame: at Day 300
it's measuring the resistance of biological tissues
at Day 300
hand grip
Time Frame: at pre transplant
hand grip
at pre transplant
hand grip
Time Frame: at Day 0
hand grip
at Day 0
hand grip
Time Frame: at Day 30
hand grip
at Day 30
hand grip
Time Frame: at Day 100
hand grip
at Day 100
hand grip
Time Frame: at Day 300
hand grip
at Day 300

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quality of life assessment,
Time Frame: at pre transplant
it's a satisfaction patient's scale
at pre transplant
Quality of life assessment,
Time Frame: at Day 0
it's a satisfaction patient's scale
at Day 0
Quality of life assessment,
Time Frame: at Day 30
it's a satisfaction patient's scale
at Day 30
Quality of life assessment,
Time Frame: at Day 100
it's a satisfaction patient's scale
at Day 100
Quality of life assessment,
Time Frame: at Day 300
it's a satisfaction patient's scale
at Day 300
number of infections,
Time Frame: at pre transplant
number of infections,
at pre transplant
number of infections,
Time Frame: at Day 0
number of infections,
at Day 0
number of infections,
Time Frame: at Day 30
number of infections,
at Day 30
number of infections,
Time Frame: at Day 100
number of infections,
at Day 100
number of infections,
Time Frame: at Day 300
number of infections,
at Day 300
number of graft versus host disease,
Time Frame: at pre transplant
number of graft versus host disease,
at pre transplant
number of graft versus host disease,
Time Frame: at Day 0
number of graft versus host disease,
at Day 0
number of graft versus host disease,
Time Frame: at Day 30
number of graft versus host disease,
at Day 30
number of graft versus host disease,
Time Frame: at Day 100
number of graft versus host disease,
at Day 100
number of graft versus host disease,
Time Frame: at Day 300
number of graft versus host disease,
at Day 300
overall survival
Time Frame: at pre transplant
overall survival
at pre transplant
overall survival
Time Frame: at Day 0
overall survival
at Day 0
overall survival
Time Frame: at Day 30
overall survival
at Day 30
overall survival
Time Frame: at Day 100
overall survival
at Day 100
overall survival
Time Frame: at Day 300
overall survival
at Day 300

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Thomas Cluzeau, Centre Hospitalier Universitaire de Nice

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 21, 2019

Primary Completion (Actual)

May 9, 2022

Study Completion (Actual)

February 12, 2023

Study Registration Dates

First Submitted

December 27, 2018

First Submitted That Met QC Criteria

January 31, 2019

First Posted (Actual)

February 4, 2019

Study Record Updates

Last Update Posted (Estimated)

February 26, 2024

Last Update Submitted That Met QC Criteria

February 23, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 18-PP-10

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Allograft

Clinical Trials on Cooking Education

Subscribe